Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 3
1986 2
1987 3
1988 2
1989 2
1990 2
1992 1
1993 1
1995 1
1999 1
2001 2
2003 1
2004 2
2005 2
2006 1
2007 1
2008 2
2009 2
2010 3
2011 2
2013 2
2014 3
2015 3
2016 1
2018 1
2019 1
2021 2
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
Vavolizza RD, Petroni GR, Mauldin IS, Chianese-Bullock KA, Olson WC, Smith KT, Dengel LT, Haden K, Grosh WW, Kaur V, Varhegyi N, Gaughan EM, Slingluff CL Jr. Vavolizza RD, et al. Among authors: grosh ww. J Immunother Cancer. 2022 Sep;10(9):e005424. doi: 10.1136/jitc-2022-005424. J Immunother Cancer. 2022. PMID: 36100309 Free PMC article. Clinical Trial.
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Slingluff CL Jr, et al. Among authors: grosh ww. Adv Immunol. 2006;90:243-95. doi: 10.1016/S0065-2776(06)90007-8. Adv Immunol. 2006. PMID: 16730266 Review.
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO, Petroni GR, Salerno EP, Lynch KT, Smolkin M, Woodson E, Chianese-Bullock KA, Olson WC, Deacon D, Patterson JW, Grosh WW, Slingluff CL. Meneveau MO, et al. Among authors: grosh ww. J Immunother Cancer. 2021 May;9(5):e002214. doi: 10.1136/jitc-2020-002214. J Immunother Cancer. 2021. PMID: 34035112 Free PMC article. Clinical Trial.
Disseminated intravascular coagulation and immune hemolytic anemia, possibly Evans syndrome, after oxaliplatin and bevacizumab infusion for metastatic colon adenocarcinoma: a case report and literature review.
Meng L, Romano A, Smith E, Macik G, Grosh WW. Meng L, et al. Among authors: grosh ww. Clin Colorectal Cancer. 2015 Mar;14(1):e1-3. doi: 10.1016/j.clcc.2014.11.005. Epub 2014 Nov 15. Clin Colorectal Cancer. 2015. PMID: 25600448 Review. No abstract available.
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Wages NA, Olson WC, Smith KT, Haden K, Dengel LT, Dickinson A, Reed C, Gaughan EM, Grosh WW, Kaur V, Varhegyi N, Smolkin M, Galeassi NV, Deacon D, Hall EH. Slingluff CL Jr, et al. Among authors: grosh ww. J Immunother Cancer. 2021 Jan;9(1):e000934. doi: 10.1136/jitc-2020-000934. J Immunother Cancer. 2021. PMID: 33479025 Free PMC article. Clinical Trial.
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.
Slingluff CL Jr, Yamshchikov GV, Hogan KT, Hibbitts SC, Petroni GR, Bissonette EA, Patterson JW, Neese PY, Grosh WW, Chianese-Bullock KA, Czarkowski A, Rehm PK, Parekh J. Slingluff CL Jr, et al. Among authors: grosh ww. Ann Surg Oncol. 2008 Dec;15(12):3538-49. doi: 10.1245/s10434-008-0046-4. Epub 2008 Oct 16. Ann Surg Oncol. 2008. PMID: 18923873 Free PMC article.
48 results